BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 29794774)

  • 41. Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines.
    Takayasu K; Arii S; Kudo M; Ichida T; Matsui O; Izumi N; Matsuyama Y; Sakamoto M; Nakashima O; Ku Y; Kokudo N; Makuuchi M
    J Hepatol; 2012 Apr; 56(4):886-92. PubMed ID: 22173160
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combination Therapy of Radiofrequency Ablation and Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Retrospective Study.
    Tang C; Shen J; Feng W; Bao Y; Dong X; Dai Y; Zheng Y; Zhang J
    Medicine (Baltimore); 2016 May; 95(20):e3754. PubMed ID: 27196501
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Chemoembolization of unresectable hepatocellular carcinoma: Decreased toxicity with slow-release doxorubicin‑eluting beads compared with lipiodol.
    Recchia F; Passalacqua G; Filauri P; Doddi M; Boscarato P; Candeloro G; Necozione S; Desideri G; Rea S
    Oncol Rep; 2012 May; 27(5):1377-83. PubMed ID: 22294036
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combined transcatheter arterial chemoembolization and local radiotherapy of unresectable hepatocellular carcinoma.
    Seong J; Keum KC; Han KH; Lee DY; Lee JT; Chon CY; Moon YM; Suh CO; Kim GE
    Int J Radiat Oncol Biol Phys; 1999 Jan; 43(2):393-7. PubMed ID: 10030267
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Transcatheter arterial chemoembolization with fine-powder cisplatin-lipiodol for HCC.
    Koizumi Y; Hirooka M; Uehara T; Kisaka Y; Uesugi K; Kumagi T; Abe M; Matsuura B; Hiasa Y; Onji M
    Hepatogastroenterology; 2011; 58(106):512-5. PubMed ID: 21661422
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Short-term therapeutic effects of transcatheter arterial chemoembolization using miriplatin-lipiodol suspension for hepatocellular carcinoma.
    Oguro S; Hashimoto S; Tanaka T; Inoue M; Nakatsuka S; Kuribayashi S; Asakura K; Kawachi S; Tanabe M; Kitagawa Y; Ebinuma H; Saito H; Hibi T
    Jpn J Radiol; 2012 Nov; 30(9):735-42. PubMed ID: 22923183
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Predicting Treatment Response to Intra-arterial Therapies for Hepatocellular Carcinoma with the Use of Supervised Machine Learning-An Artificial Intelligence Concept.
    Abajian A; Murali N; Savic LJ; Laage-Gaupp FM; Nezami N; Duncan JS; Schlachter T; Lin M; Geschwind JF; Chapiro J
    J Vasc Interv Radiol; 2018 Jun; 29(6):850-857.e1. PubMed ID: 29548875
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety and short-term therapeutic effects of miriplatin-lipiodol suspension in transarterial chemoembolization (TACE) for hepatocellular carcinoma.
    Okabe K; Beppu T; Haraoka K; Oh-Uchida Y; Yamamura S; Tomiyasu S; Yamanaka T; Sano O; Masuda T; Chikamoto A; Fujiyama S; Baba H
    Anticancer Res; 2011 Sep; 31(9):2983-8. PubMed ID: 21868548
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effect of using different embolic agents on survival in transarterial chemoembolization of hepatocellular carcinoma: gelfoam versus polyvinyl alcohol.
    Koçyiğit A; Dicle O; Göktay Y; Astarcıoğlu I
    Diagn Interv Radiol; 2014; 20(4):323-9. PubMed ID: 24808440
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Improved stability of lipiodol-drug emulsion for transarterial chemoembolisation of hepatocellular carcinoma results in improved pharmacokinetic profile: Proof of concept using idarubicin.
    Boulin M; Schmitt A; Delhom E; Cercueil JP; Wendremaire M; Imbs DC; Fohlen A; Panaro F; Herrero A; Denys A; Guiu B
    Eur Radiol; 2016 Feb; 26(2):601-9. PubMed ID: 26060065
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and efficacy of 70-150 μm and 100-300 μm drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma.
    Deipolyi AR; Oklu R; Al-Ansari S; Zhu AX; Goyal L; Ganguli S
    J Vasc Interv Radiol; 2015 Apr; 26(4):516-22. PubMed ID: 25704226
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miriplatin in patients with recurrent hepatocellular carcinoma.
    Imai N; Ikeda K; Seko Y; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Suzuki F; Suzuki Y; Arase Y; Kumada H
    Oncology; 2011; 80(3-4):188-94. PubMed ID: 21709428
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Oxaliplatin and 5-fluorouracil hepatic infusion with lipiodolized chemoembolization in large hepatocellular carcinoma.
    Li JH; Xie XY; Zhang L; Le F; Ge NL; Li LX; Gan YH; Chen Y; Zhang JB; Xue TC; Chen RX; Xia JL; Zhang BH; Ye SL; Wang YH; Ren ZG
    World J Gastroenterol; 2015 Apr; 21(13):3970-7. PubMed ID: 25852283
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Transarterial chemoembolization plus multi-imaging-guided radiofrequency ablation for elimination of hepatocellular carcinoma nodules measuring 3.1 to 5.0 cm: a single-center study.
    Haochen W; Jian W; Li S; Tianshi L; Xiaoqiang T; Yinghua Z
    J Int Med Res; 2018 Jul; 46(7):2650-2657. PubMed ID: 29683022
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Warming effect on miriplatin-lipiodol suspension as a chemotherapeutic agent for transarterial chemoembolization for hepatocellular carcinoma: preliminary clinical experience.
    Kora S; Urakawa H; Mitsufuji T; Osame A; Higashihara H; Yoshimitsu K
    Cardiovasc Intervent Radiol; 2013 Aug; 36(4):1023-9. PubMed ID: 23238851
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Transarterial embolization/chemoembolization therapy for hepatocellular carcinoma fed by adrenal artery: Preliminary results.
    Hu S; Tu J; Jia Z; Huang Y; Jiang G
    Medicine (Baltimore); 2016 Dec; 95(52):e5762. PubMed ID: 28033293
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data.
    Lencioni R; de Baere T; Soulen MC; Rilling WS; Geschwind JF
    Hepatology; 2016 Jul; 64(1):106-16. PubMed ID: 26765068
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients.
    Takayasu K; Arii S; Ikai I; Omata M; Okita K; Ichida T; Matsuyama Y; Nakanuma Y; Kojiro M; Makuuchi M; Yamaoka Y;
    Gastroenterology; 2006 Aug; 131(2):461-9. PubMed ID: 16890600
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Spectral CT in evaluating the therapeutic effect of transarterial chemoembolization for hepatocellular carcinoma: A retrospective study.
    Wang J; Shen JL
    Medicine (Baltimore); 2017 Dec; 96(52):e9236. PubMed ID: 29384909
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial.
    Ikeda M; Kudo M; Aikata H; Nagamatsu H; Ishii H; Yokosuka O; Torimura T; Morimoto M; Ikeda K; Kumada H; Sato T; Kawai I; Yamashita T; Horio H; Okusaka T;
    J Gastroenterol; 2018 Feb; 53(2):281-290. PubMed ID: 28766016
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.